Lymphoma Trial, Recruiting NCT06819475 Sponsor: St. Jude Children's Research Hospital Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT06819475
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years old or older at the time of joining, and who are enrolled in the SJLIFE study (a long-term follow-up study at St. Jude Children's Research Hospital).
  • Survivors who were treated for childhood acute lymphoblastic leukemia (ALL), a type of blood cancer diagnosed during childhood.
  • People (survivors or comparison group participants) who have lower than average muscle mass, as measured by a specific body composition score (a lean mass z-score of -0.5 or below).
  • Survivors who are able and willing to give their written agreement to take part in the trial.

Who may not be able to join:

  • Survivors who received radiation treatment to the head (cranial radiation) as part of their cancer treatment.
  • People (survivors or comparison group participants) who have implanted medical devices or metal in their body that could interfere with MRI or MRS scans (confirm with trial site).
  • People (survivors or comparison group participants) who are currently pregnant.
  • People (survivors or comparison group participants) who are taking blood-thinning medications, such as aspirin, apixaban, coumadin, edoxaban, or rivaroxaban.
  • People (survivors or comparison group participants) who weigh more than 300 pounds.
  • People (survivors or comparison group participants) who have a known allergy to local anaesthetics such as lidocaine or bupivacaine.
  • People (survivors or comparison group participants) who are unable to lie flat on their back for 90 minutes or more.
  • People (survivors or comparison group participants) who have a current history of nerve damage affecting movement in the arms or legs (peripheral motor neuropathy).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Puneet Bagga, PhD, St. Jude Children's Research Hospital

Phone: 888-226-4343

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
St. Jude Children's Research Hospital
Registry
ClinicalTrials.gov
Start date
2 June 2025
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To explore feasibility of MRI/MRS to measure OXPHOS capacity; To explore feasibility of 31P-MRS to measure OXPHOS capacity; To explore feasibility of 1H-MRS to measure OXPHOS capacity; To explore feasibility of CrCEST MRI to measure OXPHOS capacity; To explore feasibility of Fat Fraction MRI to measure OXPHOS capacity; To explore feasibility of Muscle Ultrasound to measure OXPHOS capacity; To explore feasibility of Muscle Biopsy to measure OXPHOS capacity; To explore feasibility of mtDNA-CN to measure OXPHOS capacity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov